β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including
gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small
cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially
sensitive to the drugs eventually become resistance. In this study, the investigators aim to
explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung
cancer with EGFR-TKI resistance.
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University, China
Collaborators:
General Hospital of Shenyang Military Region Liaoning Tumor Hospital & Institute Shengjing Hospital The First Affiliated Hospital of Dalian Medical University The Second Affiliated Hospital of Dalian Medical University